Aevi Genomic Medicine Inc (GNMX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Aevi Genomic Medicine Inc (GNMX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH2274D
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Aevi Genomic Medicine Inc (Aevi) formerly Medgenics is a biopharmaceutical company that focuses on the discovery, development and commercialization of new therapies platform for treating patients with rare genetic and orphan diseases. The company develops TARGT (Transduced Autologous Restorative Gene Therapy), a protein therapy that uses the patient's own skin to provide sustained production and delivery of therapeutic protein. It also produces proteins, monoclonal antibodies, peptides and other molecules. The company's products are used for treatment in the therapeutic areas of renal anemia and hematological disorders among others. It has collaborations with other research institutes and companies. Aevi is headquartered in Wayne, Pennsylvania, the US.

Aevi Genomic Medicine Inc (GNMX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Aevi Genomic Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Medgenics Enters into Agreement with Kyowa Hakko Kirin 12

Medgenics Extends Co-Development Agreement With Baxter Healthcare 13

Licensing Agreements 13

Aevi Genomic Medicine Amends its Agreement with Children's Hospital of Philadelphia 13

Medgenics Enters into Licensing Agreement with Stanford University 15

Medgenics Enters Into Licensing Agreement With Regents Of The University Of Michigan 15

Equity Offering 16

Medgenics Prices Public Offering of Shares for USD20 Million 16

Medgenics Raises USD46 Million in Public Offering of Shares 18

Medgenics Raises USD24.2 Million in Public Offering of Shares 19

Medgenics Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For US$32.5 Million 21

Medgenics Completes Private Placement Of Units For US$9.5 Million 22

Medgenics Issues Additional Shares Upon Partial Exercise Of Underwriter's Over Allotment Option 23

Acquisition 24

Medgenics Acquires NeuroFix Therapeutics 24

Aevi Genomic Medicine Inc-Key Competitors 26

Key Employees 27

Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Mar 09, 2017: Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 29

Nov 03, 2016: Medgenics Reports Third Quarter 2016 Financial Results 31

Aug 04, 2016: Medgenics Reports Second Quarter 2016 Financial Results 33

May 10, 2016: Medgenics Reports First Quarter 2016 Financial Results and NFC-1 Program Update 34

Feb 17, 2016: Medgenics Reports Fourth Quarter and Full Year 2015 Results and Advancement of NFC-1 Development Programs 35

Corporate Communications 38

Oct 10, 2016: Medgenics to Begin Trading on NASDAQ Global Market 38

Feb 03, 2016: Medgenics Promotes Brian Piper to Chief Financial Officer 39

Product News 40

10/29/2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder 40

Other Significant Developments 41

Dec 15, 2016: Medgenics Announces Name Change to Aevi Genomic Medicine 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42

List of Figures

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Aevi Genomic Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Aevi Genomic Medicine Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Aevi Genomic Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10

Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Medgenics Enters into Agreement with Kyowa Hakko Kirin 12

Medgenics Extends Co-Development Agreement With Baxter Healthcare 13

Aevi Genomic Medicine Amends its Agreement with Children's Hospital of Philadelphia 13

Medgenics Enters into Licensing Agreement with Stanford University 15

Medgenics Enters Into Licensing Agreement With Regents Of The University Of Michigan 15

Medgenics Prices Public Offering of Shares for USD20 Million 16

Medgenics Raises USD46 Million in Public Offering of Shares 18

Medgenics Raises USD24.2 Million in Public Offering of Shares 19

Medgenics Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For US$32.5 Million 21

Medgenics Completes Private Placement Of Units For US$9.5 Million 22

Medgenics Issues Additional Shares Upon Partial Exercise Of Underwriter's Over Allotment Option 23

Medgenics Acquires NeuroFix Therapeutics 24

Aevi Genomic Medicine Inc, Key Competitors 26

Aevi Genomic Medicine Inc, Key Employees 27

Aevi Genomic Medicine Inc, Subsidiaries 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16090
Site License
USD 500 INR 32180
Corporate User License
USD 750 INR 48270

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com